| pubmed-article:8605644 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0018183 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:8605644 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:8605644 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8605644 | pubmed:dateCreated | 1996-5-22 | lld:pubmed |
| pubmed-article:8605644 | pubmed:abstractText | Modern induction chemotherapy produce 60% to 80% complete remission in adults with newly diagnosed acute myelogenous leukemia (AML). A major challenge is to eradicate subclinical disease in remission and prevent leukemic relapse. Intensive post-remission chemotherapy was proved of comparable disease-free survival as BMT. | lld:pubmed |
| pubmed-article:8605644 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8605644 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8605644 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8605644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8605644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8605644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8605644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8605644 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8605644 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8605644 | pubmed:issn | 0578-1337 | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:HsuH CHC | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:TanT DTD | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:HoC HCH | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:ChanW RWR | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:ChiuC FCF | lld:pubmed |
| pubmed-article:8605644 | pubmed:author | pubmed-author:TsengC SCS | lld:pubmed |
| pubmed-article:8605644 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8605644 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:8605644 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8605644 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8605644 | pubmed:pagination | 305-11 | lld:pubmed |
| pubmed-article:8605644 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:meshHeading | pubmed-meshheading:8605644-... | lld:pubmed |
| pubmed-article:8605644 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8605644 | pubmed:articleTitle | Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. | lld:pubmed |
| pubmed-article:8605644 | pubmed:affiliation | Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C. | lld:pubmed |
| pubmed-article:8605644 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8605644 | pubmed:publicationType | Clinical Trial | lld:pubmed |
